IP Library Granted Patent US 12,329,519
Granted Patent B2
US 12,329,519 · App. 17/180,268 · Granted Jun 17, 2025

Glucose level management based on protein content of meals

Inventors: Boyi Jiang (Pasadena, CA); Yuxiang Zhong (Arcadia, CA); Sinu Bessy Abraham (Gallatin, TN); Siddharth Arunachalam (Northridge, CA); Pratik J. Agrawal (Porter Ranch, CA)
Assignee: MEDTRONIC MINIMED, INC.
A61B5/14532A61B5/4848G16H10/60G16H20/17G16H20/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,329,519
App. No.
17/180,268
Granted
Jun 17, 2025
Kind
B2
Abstract

Techniques for glucose level management are disclosed. In some examples, the techniques may involve obtaining an estimated protein value for a meal and determining an equivalent carbohydrate value for the meal based on the estimated protein value. In some examples, the techniques may involve obtaining an estimated fat value for a meal and determining, based on the estimated fat value, a glucose absorption rate resulting from consumption of the meal. In some examples, the equivalent carbohydrate value and/or the glucose absorption rate may be used to determine an amount of insulin to deliver to a patient to counteract a glucose level increase caused by consumption of the meal. The techniques may further involve generating an output indicative of the amount of insulin to deliver to the patient to counteract the glucose level increase caused by consumption of the meal.

Claims (68)

1. A system comprising:

one or more processors; and

one or more processor-readable storage media storing instructions which, when executed by the one or more processors, cause performance of:

obtaining an estimated protein value for a meal and an estimated carbohydrate value for the meal;

obtaining a patient-specific conversion factor that indicates an effect of protein on glucose levels of a patient, wherein the patient-specific conversion factor is determined based on predictions of glucose level rise for the patient using historical meal data and historical glucose levels of the patient;

converting the estimated protein value into a corresponding carbohydrate value by applying the estimated protein value to a mathematical function or by dividing the estimated protein value by the patient-specific conversion factor;

determining an equivalent carbohydrate value for the meal by adding the estimated carbohydrate value for the meal to the corresponding carbohydrate value associated with the estimated protein value;

determining, based on the equivalent carbohydrate value for the meal, an amount of insulin to deliver to a patient to counteract a glucose level increase caused by consumption of the meal; and

causing delivery of insulin to the patient, with an insulin delivery device, based on generating an output indicative of the amount of insulin to counteract the glucose level increase caused by consumption of the meal.

2. The system of claim 1 , wherein determining the amount of insulin to deliver to the patient comprises:

predicting, based on the equivalent carbohydrate value for the meal, amounts of glucose to be absorbed into a bloodstream of the patient over a duration of time due to consumption of the meal; and

determining, based on the predicted amounts of glucose to be absorbed into the bloodstream, a bolus dosage of insulin to deliver to the patient.

3. The system of claim 2 , wherein determining the amount of insulin to deliver to the patient comprises:

prior to determining the bolus dosage, obtaining an amount of a basal dosage of insulin previously delivered to the patient, and wherein determining the bolus dosage is further based on the amount of the basal dosage of insulin.

4. The system of claim 2 , wherein determining the bolus dosage comprises:

identifying a plurality of candidate dosages;

for each candidate dosage of the plurality of candidate dosages, predicting a respective amount of time within a target range for the patient's glucose levels; and

selecting a candidate dosage that results in a maximum amount of time within the target range.

5. The system of claim 1 , wherein determining the equivalent carbohydrate value comprises:

determining the conversion factor for converting the estimated protein value to a parameter approximating an effect of the protein on glucose levels of the patient; and

determining the equivalent carbohydrate for the meal based on converting the estimated protein value for the meal into the corresponding carbohydrate value using the conversion factor.

6. The system of claim 5 , wherein the conversion factor is determined based on a time of day that the patient consumes the meal.

7. The system of claim 5 , wherein the instructions, when executed by the one or more processors, cause performance of:

obtaining an estimated fat value for the meal;

determining, based on the estimated fat value, a glucose absorption rate resulting from consumption of the meal,

wherein determining the amount of insulin to deliver to the patient is based on the equivalent carbohydrate value for the meal and is further based on the glucose absorption rate resulting from consumption of the meal.

8. The system of claim 7 , wherein determining the glucose absorption rate comprises:

determining an absorption rate tuning factor for approximating an effect of fat on the glucose absorption rate; and

determining the glucose absorption rate based on the estimated fat value for the meal and the absorption rate tuning factor,

wherein the absorption rate tuning factor is determined based on historical meal data for the patient and further based on historical glucose level data for the patient.

9. A processor-implemented method comprising:

obtaining an estimated protein value for a meal and an estimated carbohydrate value for the meal;

obtaining a patient-specific conversion factor that indicates an effect of protein on glucose levels of a patient, wherein the patient-specific conversion factor is determined based on predictions of glucose level rise for the patient using historical meal data and historical glucose levels of the patient;

converting the estimated protein value into a corresponding carbohydrate value by applying the estimated protein value to a mathematical function or by dividing the estimated protein value by the patient-specific conversion factor;

determining an equivalent carbohydrate value for the meal by adding the estimated carbohydrate value for the meal to the corresponding carbohydrate value associated with the estimated protein value;

determining, based on the equivalent carbohydrate value for the meal, an amount of insulin to deliver to a patient to counteract a glucose level increase caused by consumption of the meal; and

causing delivery of insulin to the patient, with an insulin delivery device, based on generating an output indicative of the amount of insulin to counteract the glucose level increase caused by consumption of the meal.

10. The method of claim 9 , wherein determining the amount of insulin to deliver to the patient comprises:

predicting, based on the equivalent carbohydrate value for the meal, amounts of glucose to be absorbed into a bloodstream of the patient over a duration of time due to consumption of the meal; and

determining, based on the predicted amounts of glucose to be absorbed into the bloodstream, a bolus dosage of insulin to deliver to the patient.

11. The method of claim 10 , wherein determining the amount of insulin to deliver to the patient comprises:

prior to determining the bolus dosage, obtaining an amount of a basal dosage of insulin previously delivered to the patient, and wherein determining the bolus dosage is further based on the amount of the basal dosage of insulin.

12. The method of claim 10 , wherein determining the bolus dosage comprises:

identifying a plurality of candidate dosages;

for each candidate dosage of the plurality of candidate dosages, predicting a respective amount of time within a target range for the patient's glucose levels; and

selecting a candidate dosage that results in a maximum amount of time within the target range.

13. The method of claim 9 , wherein determining the equivalent carbohydrate value comprises:

determining the conversion factor for converting the estimated protein value to a parameter approximating an effect of the protein on glucose levels of the patient; and

determining the equivalent carbohydrate for the meal based on converting the estimated protein value for the meal into the corresponding carbohydrate value using the conversion factor.

14. The method of claim 13 , wherein the conversion factor is determined based on a time of day that the patient consumes the meal.

15. The method of claim 9 , further comprising:

obtaining an estimated fat value for the meal;

determining, based on the estimated fat value, a glucose absorption rate resulting from consumption of the meal,

wherein determining the amount of insulin to deliver to the patient is based on the equivalent carbohydrate value for the meal and is further based on the glucose absorption rate resulting from consumption of the meal.

16. One or more non-transitory processor-readable storage media storing instructions which, when executed by one or more processors, cause performance of:

obtaining an estimated protein value for a meal and an estimated carbohydrate value for the meal;

obtaining a patient-specific conversion factor that indicates an effect of protein on glucose levels of a patient, wherein the patient-specific conversion factor is determined based on predictions of glucose level rise for the patient using historical meal data and historical glucose levels of the patient;

converting the estimated protein value into a corresponding carbohydrate value by applying the estimated protein value to a mathematical function or by dividing the estimated protein value by the patient-specific conversion factor;

determining an equivalent carbohydrate value for the meal by adding the estimated carbohydrate value for the meal to the corresponding carbohydrate value associated with the estimated protein value;

determining, based on the equivalent carbohydrate value for the meal, an amount of insulin to deliver to a patient to counteract a glucose level increase caused by consumption of the meal; and

causing delivery of insulin to the patient, with an insulin delivery device, based on generating an output indicative of the amount of insulin to counteract the glucose level increase caused by consumption of the meal.

17. The one or more non-transitory processor-readable storage media of claim 16 , wherein determining the amount of insulin to deliver to the patient comprises:

predicting, based on the equivalent carbohydrate value for the meal, amounts of glucose to be absorbed into a bloodstream of the patient over a duration of time due to consumption of the meal;

determining, based on the predicted amounts of glucose to be absorbed into the bloodstream, a bolus dosage of insulin to deliver to the patient; and

prior to determining the bolus dosage, obtaining an amount of a basal dosage of insulin previously delivered to the patient, and wherein determining the bolus dosage is further based on the amount of the basal dosage of insulin.

18. The one or more non-transitory processor-readable storage media of claim 16 , wherein determining the equivalent carbohydrate value comprises:

determining the conversion factor for converting the estimated protein value to a parameter approximating an effect of the protein on glucose levels of the patient; and

determining the equivalent carbohydrate for the meal based on converting the estimated protein value for the meal into the corresponding carbohydrate value using the conversion factor.

Assignments (2)
SECURITY INTEREST Recorded Jan 16, 2026
From: MEDTRONIC MINIMED, INC.; COMPANION MEDICAL, INC.
To: CITIBANK, N.A.
Reel/Frame 074394/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2021
From: JIANG, BOYI; ZHONG, YUXIANG; ABRAHAM, SINU BESSY; ARUNACHALAM, SIDDHARTH; AGRAWAL, PRATIK J.
To: MEDTRONIC MINIMED, INC.
Reel/Frame 055339/0616 →
Continuity (1)
Related Publication 20220265177A1 · Aug 25, 2022
References Cited (62)
US 4562751A · Nason et al. · 1986 [cited by applicant]
US 4685903A · Cable et al. · 1987 [cited by applicant]
US 5080653A · Voss et al. · 1992 [cited by applicant]
US 5097122A · Colman et al. · 1992 [cited by applicant]
US 5505709A · Funderburk et al. · 1996 [cited by applicant]
US 5836312A · Moore · 1998 [cited by examiner]
US 6088608A · Schulman et al. · 2000 [cited by applicant]
US 6119028A · Schulman et al. · 2000 [cited by applicant]
US 6485465B2 · Moberg et al. · 2002 [cited by applicant]
US 6554798B1 · Mann et al. · 2003 [cited by applicant]
US 6558320B1 · Causey, III et al. · 2003 [cited by applicant]
US 6558351B1 · Steil et al. · 2003 [cited by applicant]
US 6589229B1 · Connelly et al. · 2003 [cited by applicant]
US 6641533B2 · Causey, III et al. · 2003 [cited by applicant]
US 6659980B2 · Moberg et al. · 2003 [cited by applicant]
US 6740072B2 · Starkweather et al. · 2004 [cited by applicant]
US 6752787B1 · Causey, III et al. · 2004 [cited by applicant]
US 6817990B2 · Yap et al. · 2004 [cited by applicant]
US 6827702B2 · Lebel et al. · 2004 [cited by applicant]
US 6932584B2 · Gray et al. · 2005 [cited by applicant]
US 7323142B2 · Pendo et al. · 2008 [cited by applicant]
US 7402153B2 · Steil et al. · 2008 [cited by applicant]
US 7621893B2 · Moberg et al. · 2009 [cited by applicant]
US 8674288B2 · Hanson et al. · 2014 [cited by applicant]
US 11723560B2 · Constantin et al. · 2023 [cited by applicant]
US 20050187749A1 · Singley · 2005 [cited by examiner]
US 20070179434A1 · Weinert · 2007 [cited by examiner]
US 20080294373A1 · Johnson · 2008 [cited by examiner]
US 20090006061A1 · Thukral · 2009 [cited by examiner]
US 20090006129A1 · Thukral · 2009 [cited by examiner]
US 20120315609A1 · Miller-Kovach · 2012 [cited by examiner]
US 20140066889A1 · Grosman et al. · 2014 [cited by applicant]
US 20180169333A1 · Grosman et al. · 2018 [cited by applicant]
US 20180200439A1 · Mazlish · 2018 [cited by examiner]
US 20180271455A1 · Zhong et al. · 2018 [cited by applicant]
US 20190321553A1 · Grosman et al. · 2019 [cited by applicant]
US 20190341137A1 · Chiu et al. · 2019 [cited by applicant]
US 20200098465A1 · Jiang et al. · 2020 [cited by applicant]
US 20200135320A1 · Vleugels · 2020 [cited by applicant]
US 20200268968A1 · Steil · 2020 [cited by examiner]
US 20200390973A1 · Wu et al. · 2020 [cited by applicant]
US 20210205534A1 · Jepson · 2021 [cited by examiner]
US 20210294946A1 · Hendriks et al. · 2021 [cited by applicant]
US 20220265926A1 · Jiang et al. · 2022 [cited by applicant]
AU 2014202301A1 · 2014 [cited by applicant]
CN 114949444A · 2022 [cited by applicant]
CN 114949445A · 2022 [cited by applicant]
EP 4047611A1 · 2022 [cited by applicant]
EP 4047612A1 · 2022 [cited by applicant]
WO 2019157102A1 · 2019 [cited by applicant]
Fletcher, Lauren, et al. “Feasibility of an implanted, closed-loop, blood-glucose control device.” Immunology 230. (Year: 2001). [cited by examiner]
Extended Search Report from counterpart European Application No. 22156969.2 dated Jul. 8, 2022, 9 pp. [cited by applicant]
Response to Extended Search Report dated Jul. 8, 2022, from counterpart European Application No. 22156969.2 filed Jan. 31, 2023, 18 pp. [cited by applicant]
Paterson et al., “Influence of Dietary Protein on Postprandial Blood Glucose Levels in Individuals with Type 1 Diabetes Mellitus Using Intensive Insulin Therapy,” Diabetic Medicine, May 2016, vol. 33, No. 5, pp. 592-598. [cited by applicant]
Bell et al., “Impact of Fat, Protein, and Glycemic Index on Postprandial Glucose Control in Type 1Diabetes: Implications for Intensive Diabetes Management in the Continuous Glucose Monitoring Era,” Diabetes Care, vol. 3… [cited by applicant]
Grosman et al., “Sensor-Augmented Pump-Based Customized Mathematical Model for Type 1 Diabetes,” Diabetes Technology and Therapeutics, vol. 20, No. 3, Mar. 2018, pp. 207-221. [cited by applicant]
U.S. Non-Final Office Action dated Jun. 14, 2023, in U.S. Appl. No. 17/180,309. [cited by applicant]
U.S. Final Office Action dated Dec. 14, 2023 in U.S. Appl. No. 17/180,309. [cited by applicant]
U.S. Advisory Action dated Mar. 13, 2024 in U.S. Appl. No. 17/180,309. [cited by applicant]
U.S. Non-Final Office Action dated Mar. 27, 2024 in U.S. Appl. No. 17/180,309. [cited by applicant]
U.S. Advisory Action dated Dec. 27, 2024 in U.S. Appl. No. 17/180,309. [cited by applicant]
U.S. Final Office Action dated Oct. 21, 2024 in U.S. Appl. No. 17/180,309. [cited by applicant]